Rockefeller Capital Management’s Keros Therapeutics KROS Stock Holding History

Rockefeller Capital Management’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.35K	Sell	126 -329	-72%	-$3.67K	﹤0.01%	4498
2026 Q1	$5.02K	Buy	455 +329	+261%	+$5.08K	﹤0.01%	4241
2025 Q4	$2.56K	Buy	+126	New	+$2.21K	﹤0.01%	4260
2023 Q1	–	Sell	-41	Closed	-$1K	–	3023
2022 Q4	$1K	Hold	41	–	–	﹤0.01%	3707
2022 Q3	$1K	Hold	41	–	–	﹤0.01%	3741
2022 Q2	$1K	Buy	+41	New	+$1.8K	﹤0.01%	3971

Other funds holding KROS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Rockefeller Capital Management's KROS Position: Q2 2026 in Review

Rockefeller Capital Management reduced its Keros Therapeutics (KROS) stake by 72% in Q2 2026, selling an estimated $3.67K and leaving 126 shares worth $1.35K. The position accounts for ﹤0.01% of the portfolio, ranked #4498.

Rockefeller Capital Management first reported a position in KROS in Q2 2022 and has held it in 6 quarters since. The position peaked at $5.02K in Q1 2026. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

Rockefeller Capital Management held 126 shares of Keros Therapeutics worth $1.35K as of Q2 2026.
Rockefeller Capital Management sold 329 Keros Therapeutics shares in Q2 2026, an estimated $3.67K.
Keros Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #4498 holding.
Rockefeller Capital Management first reported a position in Keros Therapeutics in Q2 2022 and has held it in 6 quarters since.
Rockefeller Capital Management's Keros Therapeutics position peaked at $5.02K in Q1 2026.
132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.